10-Q · May 13, 2026
Lite Strategy, Inc. reported a substantial change related to its digital assets and a continued strategic pivot towards its Litecoin treasury strategy. For the quarter ended March 31, 2026, the firm saw a change in fair…
Earnings analysis · 10-K
LITS earnings analysis
Filed September 28, 2026 · Our reading of the company's report
The latest report
Lite Strategy completed a substantial transformation into a Litecoin treasury and capital-markets business, but the transition produced no revenue and a FY2026 net loss of $71.2 million, versus $15.9 million in FY2025.…
Read full summary
Lite Strategy completed a substantial transformation into a Litecoin treasury and capital-markets business, but the transition produced no revenue and a FY2026 net loss of $71.2 million, versus $15.9 million in FY2025. The company’s $34.899 million LTC-related asset balance represents a substantial concentration of total assets, and fair-value losses were the primary driver of operating expenses. Covered calls and share repurchases provide some capital-market activity, but continued losses, low cash of $5.7 million, regulatory uncertainty, and dependence on LTC prices keep the risk/reward profile bearish.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-2.06
What stood out
-
Major Pivot to Litecoin Treasury Strategy
The company completed a strategic pivot from a pharmaceutical-focused business to a Litecoin treasury strategy. The July 2025 PIPE raised $100.0 million, and at June 30, 2026 the company held 832,716 LTC with a combined fair value of $34.899 million, including $27.272 million of digital assets and $7.627 million of digital assets receivable.
-
Covered Calls Generated Treasury Yield
Covered-call activity generated liquidity while retaining some LTC exposure: the company wrote $63.8 million of covered calls during FY2026 and received $0.9 million of proceeds. Covered calls totaling $55.9 million expired unexercised and generated $0.8 million of realized gains.
-
Legacy Operating Costs Declined
Operating costs declined sharply as prior clinical programs were discontinued. Research and development expense fell 96.9% to approximately $0.1 million from $3.9 million, while general and administrative expense decreased 11.0% to $12.0 million from $13.5 million.
-
Material Share Repurchases Continued
The company repurchased 4,378,525 shares during FY2026 at a weighted-average price of $1.12, using covered-call proceeds and digital-asset sales. It had authorized a repurchase program of up to $25.0 million and repurchased an additional 1,999,604 shares at $1.05 per share between July 1 and September 22, 2026.
-
Pipeline Repositioned to Preclinical Work
The pipeline remains focused on voruciclib and zandelisib, with new pre-clinical work in nononcologic indications beginning in the second quarter of FY2026. However, the company discontinued voruciclib’s oncology clinical development and is pursuing potential out-licensing or sale opportunities.
-
Operating Cash Burn Moderated
Cash used in operations improved to $9.1 million from $20.8 million in FY2025, although the improvement was largely offset by the treasury deployment. FY2026 net cash used in investing was $95.1 million, primarily reflecting the $100.0 million purchase of digital assets.
What to watch
-
Extreme Litecoin Concentration
The company is now highly concentrated in a single volatile asset. At June 30, 2026, LTC holdings totaled $34.899 million at fair value against total assets of $42.692 million, while the company recorded a $54.408 million change in fair value of digital assets and a $5.653 million loss on digital assets receivable during FY2026.
-
LTC Regulatory Classification Risk
Regulatory treatment remains unsettled despite the SEC’s March 17, 2026 Digital Asset Interpretation identifying LTC as a digital commodity. The filing states that courts are not bound by the interpretation and that if LTC were determined to be a security, the company could face reduced liquidity, forced liquidation of LTC holdings, or treatment as an unregistered investment company.
-
Continuing Losses and Financing Need
Liquidity remains dependent on asset sales or future capital transactions. Cash and cash equivalents declined to $5.706 million from $18.011 million, the company has accumulated losses of $475.3 million, and management states it expects operating losses and negative operating cash flows for the foreseeable future; additional equity, debt, licensing, or strategic financing may be required.
Management's outlook
No quantitative annual outlook was provided in the 10-K. Management expects operating losses and negative operating cash flows for the foreseeable future, but believes cash and digital assets will fund operations for at least the next 12 months.
Earlier filings 4
10-Q · February 17, 2026
Lite Strategy reported a net loss of $30,799 thousand (EPS -$0.82) for the three months ended December 31, 2025, driven largely by a $26,516 thousand change in fair value of digital assets recognized in operating…
10-Q · November 12, 2024
MEI Pharma reported total revenues of $0 for the three months ended September 30, 2024, down from $65,297 for the prior-year quarter, producing a net loss of $8,007, or $(1.20) per share (versus net income of $56,374,…
10-Q · May 9, 2024
MEI Pharma reported revenue of $0 for the three months ended March 31, 2024 (vs. $5,894 in the prior-year quarter) and an operating loss of $9,829 thousand (improved from an operating loss of $16,391 thousand). Net loss…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.